Oral SERD + CDK4/6 inhibitor after ESR1 emergence
When an ESR1 mutation appears, swap the aromatase inhibitor for an oral SERD and keep the CDK4/6 inhibitor going.
SERENA-6 (camizestrant switch at ctDNA ESR1 emergence, PFS HR 0.44) and EMBER-3 (imlunestrant + abemaciclib, PFS HR 0.57) show oral SERDs partner well with CDK4/6 inhibitors in resistance settings. Upfront replacement of the AI without selection failed (persevERA).
Pages like this
not linked directly; found by shared links- TermOral SERD
Shares Imlunestrant, EMBER-3, Camizestrant, HR-positive / HER2-negative breast cancer.
- IdeaMolecular-progression switching beyond ESR1
Shares Camizestrant, SERENA-6, ESR1 mutation, HR-positive / HER2-negative breast cancer.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Abemaciclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- TrialCAMBRIA-1 & CAMBRIA-2
Shares Camizestrant, HR-positive / HER2-negative breast cancer.
- PersonNicholas Turner
Shares Camizestrant, SERENA-6, HR-positive / HER2-negative breast cancer.
- IdeaStart low and step up: individualised titration of oral cancer drugs, randomised
Shares Abemaciclib, CDK4/6 inhibitors.
- TrialpostMONARCH
Shares Abemaciclib, HR-positive / HER2-negative breast cancer.
- TrialEMERALD
Shares ESR1 mutation, HR-positive / HER2-negative breast cancer.